Genen­tech gets gluey, pay­ing $47M up­front to Ori­o­n­is for de­grad­er dis­cov­ery deal

In its sec­ond deal an­nounced Wednes­day morn­ing, Roche’s Genen­tech is sign­ing up with Ori­o­n­is Bio­sciences for a mol­e­c­u­lar glue part­ner­ship in can­cer and neu­rode­gen­er­a­tion.

Genen­tech will pay Ori­o­n­is $47 mil­lion up­front, and it’s promised over $2 bil­lion in po­ten­tial down­stream mile­stones. Ori­o­n­is, a biotech com­pa­ny based out of Boston and Ghent, Bel­gium, plans to dis­cov­er and op­ti­mize small mol­e­cule mol­e­c­u­lar glues for cer­tain undis­closed tar­gets for Genen­tech, which will then take over pre­clin­i­cal and clin­i­cal de­vel­op­ment of the drug can­di­dates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER